drugset / Trial / NCT00809848

Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

NCT00809848

Phase 1/2 Completed 172 enrolled Allergan
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study will evaluate the safety and efficacy of AGN-210669 ophthalmic solution in comparison with AGN-210669 vehicle and bimatoprost ophthalmic solution dosed once-daily each morning, in subjects with ocular hypertension or primary open-angle glaucoma. Subjects will be followed for 2 weeks.

Timeline

Start
2009-02
Primary completion
2009-05
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bimatoprost Other / unclassified 0.03 %
Subject SIMENEPAG ISOPROPYL Small molecule 0.025 %
Subject SIMENEPAG ISOPROPYL Small molecule 0.05 %
Subject SIMENEPAG ISOPROPYL Small molecule 0.075 %